Earnings Estimate Forecast on Alkermes PLC(ALKS)

Alkermes PLC(ALKS): For the most recent quarter end, Alkermes PLC reported Annual Earnings of $-0.04. Based on the filings, last years Annual Earnings was, $-0.92. For the most recent quarter end, ALKS reported a surprise Earnings per Share of 78.95% . The consensus estimate for current quarter is $-0.19 and for the current fiscal year, the estimate is $-0.59. For the Next fiscal year, the estimate is $0.12 based on the consensus. Dublin 4 based Alkermes PLC Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Apr 27, 2017.

Alkermes PLC has received $-0.19 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 40.63%. Alkermes PLC reported better than expected with a surprise EPS of 78.95% or $0.15 during its most recent quarterly earnings. The Actual EPS was $-0.04 compared to the Estimated EPS of $-0.19. According to the corporate earnings calendar, Alkermes PLC will release next earnings on Apr 27, 2017 with an estimated EPS consensus of $-0.19. Based on the consensus of stock financial advisors the stock has a price target of $69.2. Current year estimate on EPS consensus is $-0.59.

For Dividend Investing Stock Market Traders Alkermes PLC has a Dividend Yield of 0% with an Annual Dividend of $0.

Alkermes Plc Last issued its quarterly earnings results on Feb 15, 2017. The company reported $0.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $0.05. The company had revenue of $213.51 million for the quarter, compared to analysts expectations of $206.38 million. The companys revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.14 EPS.

Company has reported several Insider transactions to the SEC, on Feb 16, 2017, Elliot Ehrich (EVP, R&D & CMO, Alkermes, Inc.) sold 11,000 shares at 57.02 per share price.On Feb 2, 2017, Paul J Mitchell (director) sold 1,500 shares at 54.45 per share price.On Jan 10, 2017, Shane Cooke (President, Alkermes plc) sold 550 shares at 60.27 per share price.

Alkermes plc (NASDAQ:ALKS) witnessed a decline in the market cap on Wednesday as its shares dropped 1.66% or 0.9 points. After the session commenced at $54.01, the stock reached the higher end at $54.345 while it hit a low of $53.14. With the volume soaring to 772,404 shares, the last trade was called at $53.29. The company has a 52-week high of $60.74. The company has a market cap of $8,129 million and there are 152,547,460 shares in outstanding. The 52-week low of the share price is $27.14.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Alkermes

Post Comment

*